{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:54:51Z","timestamp":1793660091094,"version":"4.5.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In X-linked hypophosphatemia (XLH), PHEX gene variants lead to elevated FGF23 production, resulting in hypophosphatemia, osteomalacia, osteomalacia-related fractures, osteoarthritis, enthesopathy, spinal stenosis, and symptoms of pain, stiffness, and decreased physical function. Burosumab is an anti-FGF23 monoclonal Ab approved for XLH treatment. Randomized studies comparing oral phosphate\/active vitamin D (Pi\/D) to burosumab in adults are lacking. This analysis, which utilized real-world data from the prospective, Americas-based XLH Disease Monitoring Program (NCT03651505), evaluated the effectiveness of burosumab vs Pi\/D, based on changes from baseline to the year 1 visit in serum phosphate, 1,25(OH)2D, PTH, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, Patient-Reported Outcomes Measurement Information System Physical Function (PROMIS PF), and Timed Up and Go performance outcome. Two cohorts of adults with XLH who either began burosumab between baseline and the year 1 visit (n\u2009=\u200965) or were on Pi\/D (n\u2009=\u200974) at study entry and did not receive burosumab were included. Inverse probability of treatment weighting was employed to adjust for potential confounding due to baseline cohort differences. At the year 1 visit, mean (SE) change from baseline was significant for burosumab vs Pi\/D in serum phosphate (0.78 [0.08] vs 0.15 [0.14] mg\/dL; p\u2009&amp;lt;\u2009.001), 1,25(OH)2D (19.41 [3.39] vs 5.49 [3.43] pg\/mL; p\u2009=\u2009.011), PTH (\u221213.82 [5.00] vs 11.79 [8.10] pg\/mL; p\u2009=\u2009.006), WOMAC pain (\u22127.50 [2.34] vs 4.47 [3.23]; p\u2009=\u2009.004), WOMAC physical function (\u22125.68 [1.96] vs 6.77 [4.85]; p\u2009=\u2009.006), and WOMAC total (\u22127.78 [2.06] vs 3.15 [3.37]; p\u2009=\u2009.005) scores, PROMIS PF (1.51 [0.73] vs \u22121.64 [1.11], p\u2009=\u2009.018), and TUG (\u22121.19 [0.42] vs 0.55 [0.43] s, p\u2009=\u2009.011). A trend towards improved WOMAC stiffness was observed for burosumab (\u221210.16 [2.85] vs \u22121.79 [3.68]; p\u2009=\u2009.086). In this real-world analysis of adults with XLH, burosumab treatment was associated with improved biochemical parameters, pain, physical function, and mobility compared with Pi\/D.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf063","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:59:18Z","timestamp":1746043158000},"page":"973-986","source":"Crossref","is-referenced-by-count":12,"title":["Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemia"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-3146","authenticated-orcid":false,"given":"Pablo","family":"Florenzano","sequence":"first","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8320165 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-3467","authenticated-orcid":false,"given":"Erik A","family":"Imel","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pediatrics, Endocrinology, Indiana University School of Medicine , Indianapolis, IN 46202 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8956","authenticated-orcid":false,"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON L8S 4L8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0779-9720","authenticated-orcid":false,"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc , Princeton, NJ 08540 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-4550","authenticated-orcid":false,"given":"Marc","family":"Vincent","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc , Princeton, NJ 08540 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Nomura","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co Ltd , Tokyo 100-0004 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3616-3332","authenticated-orcid":false,"given":"Stanley","family":"Krolczyk","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc , Novato, CA 94949 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-0920","authenticated-orcid":false,"given":"Ben","family":"Johnson","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International plc , Marlow SL7 1HZ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne","family":"Ward","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa , Ottawa, ON K1H 8L1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2025073008262146400_ref1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2025073008262146400_ref2","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025073008262146400_ref3","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"2025073008262146400_ref4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025073008262146400_ref5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00467-012-2364-9","article-title":"Hypophosphatemia and growth","volume":"28","author":"Santos","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"2025073008262146400_ref6","doi-asserted-by":"crossref","first-page":"641543","DOI":"10.3389\/fendo.2021.641543","article-title":"Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium","volume":"12","author":"Laurent","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025073008262146400_ref7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025073008262146400_ref8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","article-title":"Phenotype presentation of hypophosphatemic rickets in adults","volume":"87","author":"Beck-Nielsen","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"2025073008262146400_ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-025-00939-0","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"21","author":"Haffner","journal-title":"Nat Rev Nephrol"},{"key":"2025073008262146400_ref10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"2025073008262146400_ref11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2025073008262146400_ref12","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"2025073008262146400_ref13","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025073008262146400_ref14","doi-asserted-by":"crossref","first-page":"bvaa151","DOI":"10.1210\/jendso\/bvaa151","article-title":"X-linked hypophosphatemia: a new era in management","volume":"4","author":"Dahir","year":"2020","journal-title":"J Endocr Soc"},{"key":"2025073008262146400_ref15","first-page":"879","article-title":"A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets","volume":"75","author":"Sullivan","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2025073008262146400_ref16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2025073008262146400_ref17","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2025073008262146400_ref18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"2025073008262146400_ref19","doi-asserted-by":"crossref","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"key":"2025073008262146400_ref20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"2025073008262146400_ref21","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/CORR.0000000000000444","article-title":"What is the minimum clinically important difference for the WOMAC index after TKA?","volume":"476","author":"Clement","year":"2018","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2025073008262146400_ref22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"issue":"Supplement 3","key":"2025073008262146400_ref23","doi-asserted-by":"publisher","first-page":"S870","DOI":"10.1016\/j.jval.2019.09.2481","article-title":"Confirmatory psychometric validation of the Western Ontario McMaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar","year":"2019","journal-title":"Value Health"},{"key":"2025073008262146400_ref24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5694\/mja2.12045","article-title":"The timed up and go test","volume":"210","author":"Browne","year":"2019","journal-title":"Med J Aust"},{"key":"2025073008262146400_ref25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cup & go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"2025073008262146400_ref26","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.3390\/jcm12247618","article-title":"Evaluating the minimum clinically important difference and patient acceptable symptom state for the WOMAC osteoarthritis index after unicompartmental knee arthroplasty","volume":"12","author":"Longo","year":"2023","journal-title":"J Clin Med"},{"key":"2025073008262146400_ref27","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"issue":"Suppl 11","key":"2025073008262146400_ref28","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1002\/acr.20632","article-title":"Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS)","volume":"63","author":"Collins","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025073008262146400_ref29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/2192568220958670","article-title":"What does your PROMIS score mean? Improving the utility of patient-reported outcomes at the point of care","volume":"12","author":"Shaw","year":"2022","journal-title":"Global Spine J"},{"key":"2025073008262146400_ref30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/CORR.0000000000002046","article-title":"How do PROMIS scores correspond to common physical abilities?","volume":"480","author":"Brodke","year":"2022","journal-title":"Clin Orthop Relat Res"},{"key":"2025073008262146400_ref31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025073008262146400_ref32","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2025073008262146400_ref33","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/1475-6773.12182","article-title":"Methods for constructing and assessing propensity scores","volume":"49","author":"Garrido","year":"2014","journal-title":"Health Serv Res"},{"key":"2025073008262146400_ref34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13756-023-01347-4","article-title":"The economic burden of cardiac implantable electronic device infections in Alberta, Canada: a population-based study using validated administrative data","volume":"12","author":"Rennert-May","year":"2023","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025073008262146400_ref35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","article-title":"Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia","volume":"5","author":"Ruppe","year":"2016","journal-title":"Bone Rep"},{"key":"2025073008262146400_ref36","doi-asserted-by":"publisher","first-page":"e230242","DOI":"10.20945\/2359-4292-2023-0242","article-title":"Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: a systematic review","volume":"68","author":"Dodamani","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"9","key":"2025073008262146400_ref37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/cer-2020-0013","article-title":"Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants","volume":"9","author":"Allan","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"6","key":"2025073008262146400_ref38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025073008262146400_ref39","doi-asserted-by":"crossref","first-page":"19612","DOI":"10.1038\/srep19612","article-title":"PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism","volume":"6","author":"Akizawa","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"2025073008262146400_ref40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/ndt\/gfn592","article-title":"The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the dialysis outcomes and practice patterns study","volume":"24","author":"Tentori","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2025073008262146400_ref41","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10793","article-title":"Cardiovascular safety in postmenopausal women and men with osteoporosis treated with denosumab and zoledronic acid: a post-authorization safety study","volume":"7","author":"Spangler","year":"2023","journal-title":"JBMR Plus"},{"key":"2025073008262146400_ref42","volume-title":"NICE real-world evidence framework","author":"National Institute of Health and Care Excellence (NICE)","year":"2022"},{"key":"2025073008262146400_ref43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/sim.5991","article-title":"Variance reduction in randomised trials by inverse probability weighting using the propensity score","volume":"33","author":"Williamson","year":"2014","journal-title":"Stat Med"},{"key":"2025073008262146400_ref44","volume-title":"Adjusting for covariates in randomized clinical trials for drugs and biological products: guidance for industry","author":"United States Food and Drug Administration (FDA)","year":"2023"},{"issue":"3","key":"2025073008262146400_ref45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1214\/ss\/1042727942","article-title":"Covariance adjustment in randomized experiments and observational studies","volume":"17","author":"Rosenbaum","year":"2002","journal-title":"Stat Sci"},{"key":"2025073008262146400_ref46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/sim.4780080410","article-title":"Covariate imbalance and random allocation in clinical trials","volume":"8","author":"Senn","year":"1989","journal-title":"Stat Med"},{"key":"2025073008262146400_ref47","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1172\/JCI36479","article-title":"Endocrine functions of bone in mineral metabolism regulation","volume":"118","author":"Quarles","year":"2008","journal-title":"J Clin Invest"},{"key":"2025073008262146400_ref48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu Rev Med"},{"key":"2025073008262146400_ref49","volume-title":"The brief pain inventory: user guide","author":"Cleeland","year":"2009"},{"issue":"1","key":"2025073008262146400_ref50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf063\/63043745\/zjaf063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/8\/973\/63043745\/zjaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/8\/973\/63043745\/zjaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:26:31Z","timestamp":1753878391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/8\/973\/8123871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,5,2]]},"published-print":{"date-parts":[[2025,7,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf063","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,2]]}}}